CDR132L clinical trials
Also written CDR132L.
How each study uses CDR132L is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the CDR132L studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- CDR132L
- 5
Studies by the year they started
6 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test CDR132L.
- Dec 2026A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in Healthy ParticipantsPhase 1 · Novo Nordisk A/S
- May 2027A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular HypertrophyPhase 2 · Novo Nordisk A/S
- Nov 2027A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular HypertrophyPhase 2 · Novo Nordisk A/S
Studies
Open first, then newest update. How each study uses CDR132L is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular HypertrophyRecruitingPhase 2Novo Nordisk A/SNCT06979362Written as CDR132L
- A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in Healthy ParticipantsRecruitingPhase 1Novo Nordisk A/SNCT07656454Written as CDR132L (i.v.)
- A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular HypertrophyRecruitingPhase 2Novo Nordisk A/SNCT06979375Written as CDR132L
- Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial InfarctionCompletedPhase 2Cardior Pharmaceuticals GmbHNCT05350969Written as CDR132L
- Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac HypertrophyWithdrawnPhase 2Cardior Pharmaceuticals GmbHNCT05953831Written as CDR132L
- Clinical Study to Assess Safety, PK and PD Parameters of CDR132LCompletedPhase 1Cardior Pharmaceuticals GmbHNCT04045405Written as CDR132L